Publication | Closed Access

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

UrologyOncologyMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentProstatic DiseaseAnti-tumor ActivityPharmacologyPhase 1